Neurodegenerative diseases and therapeutic strategies using iron chelators

Journal of Trace Elements in Medicine and Biology

Volumn 31, Issue , 2015, Pages 267-273

  Ward, Roberta J ^a,b   Dexter, David T ^a   Crichton, Robert R ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Chelation; Iron; Neurodegenerative diseases

Indexed keywords

AMYLOID; COPPER; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; IRON; PLACEBO; PROTEIN AGGREGATE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; IRON CHELATING AGENT;

ALZHEIMER DISEASE; ASTROCYTE; CELL LOSS; CHELATION THERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); DEGENERATIVE DISEASE; DENTATE NUCLEUS; DISEASE COURSE; DRUG EFFICACY; FRIEDREICH ATAXIA; HUMAN; HUNTINGTON CHOREA; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; MICROGLIA; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; RED NUCLEUS; REVIEW; SUBSTANTIA NIGRA; BRAIN; DRUG EFFECTS; METABOLISM; NEURODEGENERATIVE DISEASES;

ALZHEIMER DISEASE; BRAIN; FRIEDREICH ATAXIA; HUMANS; IRON; IRON CHELATING AGENTS; MULTIPLE SCLEROSIS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE;

EID: 84929654868     PISSN: 0946672X     EISSN: 18783252     Source Type: Journal    
DOI: 10.1016/j.jtemb.2014.12.012     Document Type: Review

References (43)

1. European Commission Appendix 1: overall vision for the Human Brain Project 604102 (HBP), annex 1 - part B, version of August 16, 2013 2013, 1-78.
2. Plassman B.L., Langa K.M., Fisher G.G., Heeringa S.G., Weir D.R., Ofstedal M.B., et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 2007, 29:125-132.
3. Crichton R.R. Biological inorganic chemistry: a new introduction to molecular structure and function 2012, Elsevier, Oxford. 2nd ed.
4. Xia Z., Storm D.R. The role of calmodulin as a signal integrator for synaptic plasticity. Nat Rev Neurosci 2005, 6:267-276.
5. 2+/calmodulin-dependent protein kinase II: the role of structure and autoregulation in cellular function. Annu Rev Biochem 2002, 71:473-510.
6. 2+/calmodulin-dependent protein kinase in rat brain. J Neurosci 1985, 5:3270-3277.
7. Bitanihirwe B.K., Cunningham M.G. Zinc: the brain's dark horse. Synapse 2009, 63:1029-1049.
8. Lutsenko S., Bhattacharjee A., Hubbard A.L. Copper handling machinery of the brain. Metallomics 2010, 2:596-608.
9. Crichton R.R. Iron metabolism from molecular mechanisms to clinical consequences 2009, John Wiley & Sons, Chichester. 3rd ed.
10. Crichton R.R., Ward R.J. Metal-based neurodegeneration: from molecular mechanisms to therapeutic strategies 2006, John Wiley & Sons, Chichester.
11. Crichton R.R., Ward R.J. Metal-based neurodegeneration: from molecular mechanisms to therapeutic strategies 2014, John Wiley & Sons, Chichester. 2nd ed.
12. Crichton R.R., Pierre J.L. Old iron, young copper: from Mars to Venus. Biometals 2001, 14:99-112.
13. Pierre J.L., Fontecave M., Crichton R.R. Chemistry for an essential biological process: the reduction of ferric iron. Biometals 2002, 15:341-346.
14. Sayre L.M., Lin D., Yuan Q., Zhu X., Tang X. Protein adducts generated from products of lipid oxidation: focus on HNE and one. Drug Metab Rev 2006, 38:651-675.
15. Schneider C., Porter N.A., Brash A.R. Routes to 4-hydroxynonenal: fundamental issues in the mechanisms of lipid peroxidation. J Biol Chem 2008, 283:15539-15543.
16. Dalle-Donne I., Giustarini D., Colombo R., Rossi R., Milzani A. Protein carbonylation in human diseases. Trends Mol Med 2003, 9:169-176.
17. Grimsrud P.A., Xie H., Griffin T.J., Bernlohr D.A. Oxidative stress and covalent modification of protein with bioactive aldehydes. J Biol Chem 2008, 283:21837-21841.
18. Chiti F., Dobson C.M. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 2006, 75:333-366.
19. Sipe J.D., Cohen A.S. Review: history of the amyloid fibril. J Struct Biol 2000, 130:88-98.
20. Greenwald J., Riek R. Biology of amyloid: structure, function, and regulation. Structure 2010, 18:1244-1260.
21. Astbury W.T., Dickinson S., Bailey K. The X-ray interpretation of denaturation and the structure of the seed globulins. Biochem J 1935, 29:2351-2360.
22. Sunde M., Serpell L.C., Bartlam M., Fraser P.E., Pepys M.B., Blake C.C. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol 1997, 273:729-739.
23. Eisenberg D., Jucker M. The amyloid state of proteins in human diseases. Cell 2012, 148:11880-21203.
24. Dobson C.M. Protein misfolding, evolution and disease. Trends Biochem Sci 1999, 24:329-332.
25. Boddaert N., Le Quan Sang K.H., Rötig A., Leroy-Willig A., Gallet S., Brunelle F., et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007, 110:401-408.
26. Hocq A., Brouette N., Saussez S., Luhmer M., Gillis P., Gossuin Y. Variable-field relaxometry of iron-containing human tissues: a preliminary study. Contrast Media Mol Imaging 2009, 4:157-164.
27. Kwiatkowski A., Ryckewaert G., Jissendi Tchofo P., Moreau C., Vuillauma I., Chinnery P.F., et al. Long-term improvement under deferiprone in a case of neurodegeneration with brain iron accumulation. Parkinsonism Relat Disord 2010, 18:110-112.
28. Devos D., Moreau C., Devedjian J.C., Kluza J., Laloux C., Jonneaux A., et al. Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal 2013, 21(2):195-210.
29. Moreau C., Devedjian J.-C., Kluza J., Laloux C., Jonneaux A., Petrault M., et al. Targrting brain chelatable iron as a therapeutic strategy for Parkinson's disease. Translational and Clinical Studies Podium Abstract 52, BioIron 2013, London 2013.
30. Dexter D., Ward R., Crichton R., Kallo V., Srai S.K. Altered brain iron homeostasis in Parkinson's disease and potential for iron chelation. Poster Abstract 208, BioIron 2013, London 2013.
31. Rogers J.T., Randall J.D., Cahill C.M., Eder P.S., Huang X., Gunshin H., et al. An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 2002, 277:45518-45528.
32. Crapper McLachian D.R., Dalton A.J., Kruck T.P., Bell M.Y., Smith W.L., Kalow W., et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 1991, 1337:1304-1308.
33. Lannfelt L., Blennow K., Zetterberg H., Batsman S., Ames D., Harrison J., et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2008, 7:779-786.
34. Velasco-Sanchez D., Aracil A., Montero R., Mas A., Jiménez L., O'Callaghan M., et al. Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum 2011, 10:1-8.
35. Stephenson E., Nethoo N., Mahjoub Y., Dunn J., Yong V.W. Iron in multiple sclerosis: roles in neurodegeneration and repair. Nat Rev Neurobiol 2014, 10:459-468.
36. London A., Cohen M., Schwartz M. Microglia and monocyte-derived macrophages: functionally distinct populations that act in concert in CNS plasticity and repair. Front Cell Neurosci 2013, 7:34.
37. Sastre M., Katsouri L., Birch A., Renziehausen A., Dexter D.T., Crichton R.R., et al. Neuroinflammation in Alzheimer's, Parkinson's and Huntington diseases in neuroimmunology 2015, 111-150. Wiley and Son, Chichester, UK. S. Amor, N. Woodroofe (Eds.).
38. Pisanu A., Lecca D., Mulas G., Wardas J., Simbula G., Spiga S., et al. Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease. Neurobiol Dis 2014, 71:280-291.
39. McGeer E.G., McGeer P.L. Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. J Alzheimers Dis 2010, 19(1):355-361.
40. Varnum M.M., Ikezu T. The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain. Arch Immunol Ther Exp (Warsz) 2012, 60(4):251-266.
41. Wilcock D.M. A changing perspective on the role of neuroinflammation in Alzheimer's disease. Int J Alzheimers Dis 2012, 2012:495243.
42. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372(9648):1502-1517.
43. Fumagalli M., Lecca D., Abbracchio M.P. Role of purinergic signalling in neuro-immune cells and adult neural progenitors. Front Biosci (Landmark Ed) 2011, 16:2326-2341.